New Indian Health Magazine Features EECP® Therapy In Its Cover Story 

Vasomedical Applauds the International EECP® Therapist Association Call for International EECP® Therapy Week in Recognition of American Heart Month

Chapter Dedicated to EECP® Therapy in New Textbook on Coronary Artery Disease

Vasomedical Recorded Record Net Income of $2.47 Million for the Second Quarter of Fiscal 2012

More >>

January 20, 2012

Chapter Dedicated to EECP® Therapy in New Textbook on Coronary Artery Disease

Coronary Artery Disease: New Approaches without Traditional Revascularization
by Gregory W. Barsness and David R. Holmes (Hardcover - Dec 6, 2011)

WESTBURY, N.Y. January 20, 2012 - In response to the growing recognition of past failures in the treatment of “untreatable” patients, Drs. Gregory Barsness and David Holmes Jr. have edited the first textbook of its kind, as a framework within which a practicing clinician can expand on current practices and find insightful resources in dealing with the unmet need to provide treatment for the “unrevascularizable” but still symptomatic patient. Dr. Barsness is an Assistant Professor of Medicine and Dr. Holmes Jr. is a Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. Dr. Holmes Jr. is currently the President of the American College of Cardiology.

Included in the textbook is a chapter by Dr. Bradley Bart, Chief of Cardiology at Hennepin County Medical Center in Minneapolis, MN, on Enhanced External Counterpulsation (EECP®) Therapy. In this chapter, Dr. Bart thoroughly covers the initial development, clinical applications and possible mechanisms of action of counterpulsation therapy as currently used in the treatment of ischemic heart disease. Dr. Bart is also the Director of Clinical Programs at Hennepin County Medical Center, including nuclear cardiology, EECP® Therapy(enhanced external counterpulsation for the treatment of severe angina), therapeutic hypothermia for the treatment of cardiac arrest survivors, and ultrafiltration for advanced heart failure.

Both Drs. Barsness and Holmes have been actively involved in clinical research and published articles demonstrating the safety and effectiveness of EECP® Therapy. They have also been involved in the program at Mayo Clinic providing EECP® Therapy as a non-invasive treatment option for their patients. Dr. Bart has been involved in clinical research, and published articles on the benefits of EECP® therapy in cardiovascular disease management. All three continue to be advocates of EECP® therapy for their patients.  

To get more information about or obtain the book please click on the link below: http://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Daps&field-keywords=coronary+artery+disease+gregory+barsness&x=0&y=0

Vasomedical, Inc. is engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of cardiovascular diseases and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. The Company also provides other noninvasive medical equipment including Holter monitors and ambulatory blood pressure monitors.

Vaso Diagnostics d/b/a VasoHealthcare, a wholly owned subsidiary of Vasomedical, Inc., is a professional sales representation organization offering vendors of medical devices an alternative third party sales channel. Through an agreement with GE Healthcare, it is currently engaged as an exclusive sales representative for certain GE Healthcare products.

Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.